Index RUT
P/E -
EPS (ttm) -5.42
Insider Own 2.33%
Shs Outstand 96.44M
Perf Week 6.28%
Market Cap 2.17B
Forward P/E -
EPS next Y -5.64
Insider Trans -2.33%
Shs Float 94.19M
Perf Month -10.36%
Income -481.19M
PEG -
EPS next Q -1.37
Inst Own 88.81%
Short Float 15.49%
Perf Quarter -5.54%
Sales 36.27M
P/S 59.83
EPS this Y -1.29%
Inst Trans -0.30%
Short Ratio 9.68
Perf Half Y -5.58%
Book/sh 11.29
P/B 1.99
EPS next Y -2.69%
ROA -34.11%
Short Interest 14.59M
Perf Year -40.38%
Cash/sh 9.46
P/C 2.38
EPS next 5Y 30.00%
ROE -42.10%
52W Range 19.37 - 47.48
Perf YTD -26.21%
Dividend Est. -
P/FCF -
EPS past 5Y -22.30%
ROI -41.96%
52W High -52.61%
Beta 1.85
Dividend TTM -
Quick Ratio 8.67
Sales past 5Y 12.09%
Gross Margin 75.26%
52W Low 16.16%
ATR (14) 1.31
Dividend Ex-Date -
Current Ratio 8.67
EPS Y/Y TTM 12.31%
Oper. Margin -1420.51%
RSI (14) 44.72
Volatility 6.72% 4.90%
Employees 526
Debt/Eq 0.11
Sales Y/Y TTM -30.40%
Profit Margin -1326.51%
Recom 1.54
Target Price 69.57
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -4.64%
Payout -
Rel Volume 1.12
Prev Close 21.40
Sales Surprise -115.04%
EPS Surprise -1.49%
Sales Q/Q -114.12%
Earnings Feb 22 BMO
Avg Volume 1.51M
Price 22.50
SMA20 -1.78%
SMA50 -14.34%
SMA200 -25.96%
Trades
Volume 1,684,893
Change 5.14%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Downgrade
Goldman
Buy → Neutral
$136 → $32
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Apr-13-23 Initiated
Canaccord Genuity
Buy
$66
Mar-21-23 Initiated
Bernstein
Outperform
$54
Mar-14-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$54 → $57
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$67
Jan-24-23 Upgrade
Citigroup
Sell → Neutral
$48 → $39
Jan-19-23 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Oct-11-22 Initiated
Morgan Stanley
Overweight
$84
Sep-21-22 Initiated
JP Morgan
Overweight
$85
Sep-01-22 Initiated
Citigroup
Sell
$50
Jun-17-22 Initiated
BMO Capital Markets
Market Perform
$54
Jun-16-22 Initiated
BofA Securities
Buy
$70
Apr-28-22 Initiated
Credit Suisse
Outperform
$100
Feb-18-22 Initiated
William Blair
Outperform
$144
Feb-07-22 Upgrade
Oppenheimer
Perform → Outperform
$145 → $150
Jan-31-22 Initiated
Cowen
Outperform
Jan-07-22 Initiated
Piper Sandler
Overweight
$171
Oct-05-21 Initiated
Guggenheim
Buy
$170
Sep-24-21 Initiated
Stifel
Buy
$173
Show Previous Ratings
Apr-29-24 07:30AM
Apr-25-24 11:21AM
10:01AM
Apr-14-24 05:55AM
Apr-12-24 04:50AM
04:50AM
Loading…
Apr-09-24 04:50AM
Mar-28-24 05:55AM
Mar-21-24 05:29PM
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
09:30AM
Loading…
Feb-28-24 09:30AM
Feb-27-24 11:55AM
09:35AM
Feb-23-24 12:22PM
11:12AM
09:55AM
Feb-22-24 10:53PM
(Thomson Reuters StreetEvents)
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Feb-14-24 07:30AM
06:05AM
Loading…
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Feb-08-24 01:15PM
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
12:28PM
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
08:55AM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
05:52AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
12:47PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
(The Wall Street Journal)
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
06:30AM
Nov-09-23 04:06PM
03:37PM
08:29AM
07:30AM
Nov-06-23 08:02AM
(Investor's Business Daily)
Nov-02-23 07:00AM
06:45AM
Oct-30-23 03:46PM
10:00AM
Oct-28-23 07:30AM
Oct-26-23 10:02AM
07:30AM
Oct-23-23 09:40AM
08:45AM
Oct-21-23 05:00AM
Oct-19-23 11:46AM
Oct-18-23 04:10PM
(Investor's Business Daily)
07:00AM
Oct-16-23 12:39PM
10:43AM
Oct-14-23 12:20PM
Oct-13-23 08:38AM
Oct-12-23 08:57AM
Oct-10-23 02:00PM
10:07AM
Oct-06-23 04:59AM
Oct-05-23 09:15AM
Oct-04-23 09:27AM
Oct-03-23 10:07AM
07:58AM
07:08AM
07:00AM
Sep-23-23 09:45AM
Sep-10-23 08:15AM
Sep-09-23 03:59PM
Sep-06-23 02:00PM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BASTA JAMES EVP, General Counsel Mar 04 '24 Sale 32.99 2,297 75,778 81,571 Mar 05 04:10 PM Clark Eliana EVP, Chief Technical Officer Mar 04 '24 Sale 32.99 605 19,959 71,470 Mar 05 04:10 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 08 '24 Sale 28.87 2,275 65,682 43,927 Jan 10 04:15 PM LEONARD JOHN M President and CEO Jan 03 '24 Sale 29.46 19,223 566,310 846,486 Jan 05 04:51 PM Lebwohl David EVP, Chief Medical Officer Jan 03 '24 Sale 29.46 5,843 172,135 54,372 Jan 05 04:50 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 03 '24 Sale 29.46 5,532 162,973 46,202 Jan 05 04:50 PM Goddard Glenn EVP, Chief Financial Officer Jan 03 '24 Sale 29.46 5,365 158,053 40,585 Jan 05 04:49 PM Clark Eliana EVP, Chief Technical Officer Jan 03 '24 Sale 29.50 4,608 135,954 40,845 Jan 05 04:44 PM Hicks Derek EVP, Chief Business Officer Jan 03 '24 Sale 29.46 3,877 114,216 36,987 Jan 05 04:46 PM BASTA JAMES EVP, General Counsel Jan 03 '24 Sale 29.46 3,805 112,095 51,474 Jan 05 04:45 PM Bhanji Muna Director Oct 31 '23 Sale 23.90 265 6,334 11,996 Nov 02 04:42 PM Bhanji Muna Director Jul 31 '23 Sale 42.33 265 11,217 12,261 Aug 02 05:19 PM Bhanji Muna Director Jul 06 '23 Sale 39.30 1,867 73,373 12,526 Jul 10 05:21 PM Clark Eliana EVP, Chief Technical Officer Jul 03 '23 Sale 40.51 360 14,584 45,146 Jul 06 03:34 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Option Exercise 12.27 5,000 61,350 50,146 Jun 22 05:52 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Sale 45.00 5,000 225,000 45,146 Jun 22 05:52 PM
Index RUT
P/E -
EPS (ttm) -5.45
Insider Own 3.28%
Shs Outstand 101.64M
Perf Week -5.16%
Market Cap 6.63B
Forward P/E -
EPS next Y -3.28
Insider Trans -6.45%
Shs Float 101.15M
Perf Month -10.71%
Income -526.24M
PEG -
EPS next Q -1.14
Inst Own 108.39%
Short Float 13.88%
Perf Quarter -18.89%
Sales 7.53M
P/S 880.11
EPS this Y 18.23%
Inst Trans -1.40%
Short Ratio 6.95
Perf Half Y 97.48%
Book/sh -3.80
P/B -
EPS next Y 26.51%
ROA -57.23%
Short Interest 14.04M
Perf Year 67.78%
Cash/sh 5.88
P/C 10.77
EPS next 5Y 15.00%
ROE -
52W Range 25.98 - 110.25
Perf YTD -24.10%
Dividend Est. -
P/FCF -
EPS past 5Y -22.79%
ROI -154.11%
52W High -42.52%
Beta 0.72
Dividend TTM -
Quick Ratio 6.12
Sales past 5Y 12.30%
Gross Margin -82.78%
52W Low 143.92%
ATR (14) 2.85
Dividend Ex-Date -
Current Ratio 6.12
EPS Y/Y TTM -28.21%
Oper. Margin -6589.71%
RSI (14) 39.34
Volatility 3.30% 3.92%
Employees 423
Debt/Eq -
Sales Y/Y TTM -92.04%
Profit Margin -6988.63%
Recom 1.44
Target Price 96.06
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 4.77%
Payout -
Rel Volume 0.61
Prev Close 61.32
Sales Surprise -78.05%
EPS Surprise -43.97%
Sales Q/Q -14.56%
Earnings May 08 AMC
Avg Volume 2.02M
Price 63.37
SMA20 -7.71%
SMA50 -8.75%
SMA200 23.01%
Trades
Volume 1,232,149
Change 3.34%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-24-24 Downgrade
UBS
Buy → Neutral
$61 → $92
Jan-05-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$60 → $90
Nov-09-23 Initiated
Goldman
Buy
$50
Nov-07-23 Initiated
B. Riley Securities
Buy
$66
Aug-15-23 Initiated
SVB Securities
Outperform
$58
Feb-17-23 Initiated
BofA Securities
Neutral
$49
Dec-23-22 Reiterated
Needham
Buy
$60 → $58
Dec-20-22 Initiated
Truist
Buy
$60
Oct-11-22 Initiated
UBS
Buy
$80
Jan-28-22 Initiated
Goldman
Buy
$74
Dec-22-21 Initiated
Oppenheimer
Outperform
$55
Dec-10-21 Initiated
JP Morgan
Overweight
$58
Oct-07-21 Initiated
Jefferies
Buy
$75
Mar-12-21 Initiated
Wolfe Research
Outperform
$50
Feb-18-21 Initiated
Barclays
Overweight
$28
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$22 → $41
Oct-29-20 Initiated
Goldman
Neutral
$16
Jul-10-20 Initiated
Raymond James
Strong Buy
$39
May-05-20 Initiated
Mizuho
Buy
$31
Apr-09-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$25
Show Previous Ratings
May-01-24 10:01AM
Apr-29-24 04:00PM
Apr-26-24 04:44PM
06:00AM
Apr-24-24 04:00PM
09:27AM
Loading…
Apr-10-24 09:27AM
07:30AM
Apr-09-24 07:00PM
Apr-05-24 07:30AM
Apr-02-24 04:00PM
Apr-01-24 04:00PM
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
02:25PM
Loading…
Mar-13-24 02:25PM
Mar-12-24 06:46AM
(Thomson Reuters StreetEvents)
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
(FierceBiotech.com) -9.75%
10:22AM
07:30AM
Feb-27-24 05:10PM
04:42PM
04:17PM
(Associated Press Finance)
04:00PM
Feb-13-24 04:00PM
Feb-12-24 12:38AM
10:01AM
Loading…
Feb-09-24 10:01AM
(Investor's Business Daily)
Feb-08-24 09:10AM
Feb-06-24 04:00PM
Feb-05-24 05:30PM
(The Wall Street Journal)
Jan-29-24 07:30AM
Jan-25-24 07:30AM
Jan-18-24 01:00PM
Jan-12-24 04:40PM
02:47PM
01:07PM
05:27AM
Jan-11-24 04:22PM
04:05PM
12:58PM
(The Wall Street Journal)
12:54PM
12:47PM
(The Wall Street Journal)
12:30PM
Jan-10-24 01:04PM
Jan-09-24 01:17PM
Jan-08-24 05:14PM
(The Wall Street Journal) +15.29%
04:42PM
(Investor's Business Daily)
02:12PM
(Investor's Business Daily)
01:11PM
(The Wall Street Journal)
01:05PM
Jan-03-24 04:00PM
06:45AM
Jan-02-24 04:00PM
Dec-29-23 01:01PM
Dec-28-23 03:09PM
(Investor's Business Daily)
02:43PM
09:44AM
Dec-27-23 05:26PM
(Yahoo Finance Video) +82.54%
03:52PM
01:59PM
01:00PM
12:21PM
(Associated Press Finance)
09:41AM
08:34AM
07:39AM
07:32AM
07:30AM
Dec-26-23 04:00PM
Dec-15-23 10:22AM
Dec-07-23 07:30AM
Dec-01-23 04:00PM
Nov-29-23 04:00PM
Nov-10-23 03:04PM
Nov-04-23 12:16PM
Nov-03-23 04:00PM
11:43AM
(Thomson Reuters StreetEvents)
11:20AM
Nov-02-23 06:59PM
05:25PM
04:24PM
(Associated Press Finance)
04:00PM
09:55AM
Nov-01-23 04:00PM
Oct-31-23 02:24PM
12:43PM
Oct-26-23 09:08PM
Oct-23-23 04:00PM
Oct-19-23 07:30AM
Oct-09-23 07:53AM
Oct-06-23 12:45PM
Oct-05-23 04:00PM
Oct-03-23 04:00PM
Oct-02-23 04:00PM
Sep-28-23 07:30AM
Sep-15-23 01:05AM
Sep-14-23 01:02AM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HENDERSON JOHN T Director Apr 25 '24 Sale 64.54 10,562 681,671 32,070 Apr 25 06:54 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Option Exercise 6.67 28,605 190,795 171,172 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Sale 74.31 32,605 2,422,918 138,567 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Option Exercise 6.67 28,604 190,789 167,577 Mar 05 04:05 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Sale 67.56 32,604 2,202,606 138,973 Mar 05 04:05 PM HENDERSON JOHN T Director Feb 14 '24 Option Exercise 4.44 5,000 22,200 47,632 Feb 14 04:04 PM HENDERSON JOHN T Director Feb 14 '24 Sale 76.48 5,000 382,400 42,632 Feb 14 04:04 PM Blum Robert I President & CEO Feb 13 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 13 04:01 PM Blum Robert I President & CEO Feb 13 '24 Sale 76.85 12,500 960,625 441,797 Feb 13 04:01 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Option Exercise 6.67 28,605 190,795 175,578 Feb 06 04:43 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Sale 79.30 32,605 2,585,496 142,973 Feb 06 04:43 PM Blum Robert I President & CEO Jan 31 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 02 04:41 PM Blum Robert I President & CEO Jan 31 '24 Sale 79.57 12,500 994,625 441,797 Feb 02 04:41 PM Blum Robert I President & CEO Jan 19 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 22 05:19 PM Blum Robert I President & CEO Jan 19 '24 Sale 81.42 12,500 1,017,750 441,797 Jan 22 05:19 PM HENDERSON JOHN T Director Jan 12 '24 Option Exercise 4.44 5,000 22,200 47,632 Jan 12 05:20 PM HENDERSON JOHN T Director Jan 12 '24 Sale 85.14 5,000 425,700 42,632 Jan 12 05:20 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Option Exercise 7.96 11,678 92,957 162,651 Jan 04 04:36 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Sale 86.98 15,678 1,363,712 146,973 Jan 04 04:36 PM Blum Robert I President & CEO Jan 02 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 02 05:55 PM Blum Robert I President & CEO Jan 02 '24 Sale 85.08 12,500 1,063,500 441,797 Jan 02 05:55 PM WIERENGA WENDALL Director Dec 27 '23 Option Exercise 4.44 10,000 44,400 23,653 Dec 27 04:11 PM WIERENGA WENDALL Director Dec 27 '23 Sale 73.60 10,000 736,000 18,653 Dec 27 04:11 PM HENDERSON JOHN T Director Dec 18 '23 Option Exercise 6.72 13,020 87,494 44,838 Dec 19 04:12 PM Blum Robert I President & CEO Dec 18 '23 Option Exercise 6.67 12,500 83,375 454,297 Dec 19 04:13 PM Blum Robert I President & CEO Dec 18 '23 Sale 36.95 12,500 461,875 441,797 Dec 19 04:13 PM HENDERSON JOHN T Director Dec 18 '23 Sale 36.34 2,458 89,324 42,380 Dec 19 04:12 PM Blum Robert I President & CEO Nov 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Dec 01 04:15 PM Blum Robert I President & CEO Nov 30 '23 Sale 32.99 12,500 412,375 441,417 Dec 01 04:15 PM Blum Robert I President & CEO Nov 15 '23 Option Exercise 6.67 12,500 83,375 453,917 Nov 15 05:22 PM Blum Robert I President & CEO Nov 15 '23 Sale 34.57 12,500 432,125 441,417 Nov 15 05:22 PM Malik Fady Ibraham EVP Research & Development Nov 09 '23 Sale 35.40 2,500 88,500 150,664 Nov 09 04:35 PM Blum Robert I President & CEO Oct 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 30 04:02 PM Blum Robert I President & CEO Oct 30 '23 Sale 32.17 12,500 402,125 441,417 Oct 30 04:02 PM Blum Robert I President & CEO Oct 16 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 16 05:57 PM Blum Robert I President & CEO Oct 16 '23 Sale 33.70 12,500 421,250 441,417 Oct 16 05:57 PM Malik Fady Ibraham EVP Research & Development Oct 12 '23 Sale 35.89 2,500 89,725 153,164 Oct 12 06:39 PM Blum Robert I President & CEO Oct 06 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 06 04:52 PM Blum Robert I President & CEO Oct 06 '23 Sale 30.00 12,500 375,000 441,417 Oct 06 04:52 PM Malik Fady Ibraham EVP Research & Development Sep 14 '23 Sale 34.86 2,500 87,150 155,664 Sep 14 04:09 PM Blum Robert I President & CEO Sep 13 '23 Option Exercise 6.67 12,500 83,375 453,917 Sep 13 04:09 PM Blum Robert I President & CEO Sep 13 '23 Sale 34.90 12,500 436,206 441,417 Sep 13 04:09 PM Blum Robert I President & CEO Aug 25 '23 Option Exercise 7.70 12,500 96,275 453,917 Aug 28 06:45 PM Blum Robert I President & CEO Aug 25 '23 Sale 33.99 12,500 424,875 441,417 Aug 28 06:45 PM WIERENGA WENDALL Director Aug 21 '23 Option Exercise 6.72 6,020 40,454 24,225 Aug 21 04:01 PM WIERENGA WENDALL Director Aug 21 '23 Sale 32.02 6,020 192,760 18,205 Aug 21 04:01 PM Blum Robert I President & CEO Aug 11 '23 Option Exercise 9.54 12,500 119,287 453,125 Aug 11 04:18 PM Blum Robert I President & CEO Aug 11 '23 Sale 32.37 12,500 404,589 441,417 Aug 11 04:18 PM Malik Fady Ibraham EVP Research & Development Aug 10 '23 Sale 31.70 2,500 79,250 158,164 Aug 10 04:14 PM Blum Robert I President & CEO Aug 01 '23 Option Exercise 9.65 12,500 120,625 452,108 Aug 01 04:57 PM Blum Robert I President & CEO Aug 01 '23 Sale 32.63 12,500 407,856 441,417 Aug 01 04:57 PM Blum Robert I President & CEO Jul 13 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 13 04:10 PM Blum Robert I President & CEO Jul 13 '23 Sale 35.28 12,500 440,940 441,417 Jul 13 04:10 PM Malik Fady Ibraham EVP Research & Development Jul 13 '23 Sale 35.37 2,500 88,425 160,664 Jul 13 04:09 PM Bhanji Muna Director Jul 07 '23 Sale 34.12 2,000 68,235 14,031 Jul 07 04:17 PM Blum Robert I President & CEO Jul 03 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 05 04:18 PM Blum Robert I President & CEO Jul 03 '23 Sale 32.60 12,500 407,500 441,417 Jul 05 04:18 PM Blum Robert I President & CEO Jun 12 '23 Option Exercise 9.65 12,500 120,625 453,917 Jun 12 05:49 PM Blum Robert I President & CEO Jun 12 '23 Sale 37.06 12,500 463,250 441,417 Jun 12 05:49 PM Malik Fady Ibraham EVP Research & Development Jun 08 '23 Sale 38.07 2,500 95,175 163,164 Jun 08 04:31 PM Blum Robert I President & CEO May 31 '23 Option Exercise 9.65 12,500 120,625 453,558 Jun 01 05:06 PM Blum Robert I President & CEO May 31 '23 Sale 37.67 12,500 470,875 441,058 Jun 01 05:06 PM Blum Robert I President & CEO May 16 '23 Option Exercise 9.65 12,500 120,625 453,558 May 16 04:33 PM Blum Robert I President & CEO May 16 '23 Sale 37.41 12,500 467,625 441,058 May 16 04:33 PM HENDERSON JOHN T Director May 15 '23 Option Exercise 6.78 4,166 28,245 29,586 May 15 04:07 PM HENDERSON JOHN T Director May 15 '23 Sale 37.77 4,166 157,350 25,420 May 15 04:07 PM Malik Fady Ibraham EVP Research & Development May 11 '23 Sale 39.50 1,787 70,586 165,396 May 11 05:26 PM Malik Fady Ibraham EVP Research & Development May 03 '23 Option Exercise 7.96 7,000 55,720 174,183 May 03 04:46 PM Malik Fady Ibraham EVP Research & Development May 03 '23 Sale 40.00 7,000 280,000 167,183 May 03 04:46 PM
Index RUT
P/E -
EPS (ttm) -1.02
Insider Own 1.67%
Shs Outstand 75.07M
Perf Week 1.16%
Market Cap 1.51B
Forward P/E -
EPS next Y -0.04
Insider Trans -1.57%
Shs Float 73.81M
Perf Month -1.85%
Income -74.40M
PEG -
EPS next Q -0.16
Inst Own 103.48%
Short Float 4.93%
Perf Quarter -19.54%
Sales 361.05M
P/S 4.19
EPS this Y 74.73%
Inst Trans 0.36%
Short Ratio 5.36
Perf Half Y -0.45%
Book/sh 14.25
P/B 1.41
EPS next Y 84.39%
ROA -6.40%
Short Interest 3.64M
Perf Year -11.87%
Cash/sh 2.88
P/C 6.98
EPS next 5Y -
ROE -7.02%
52W Range 18.61 - 30.52
Perf YTD -26.83%
Dividend Est. -
P/FCF 44.11
EPS past 5Y -10.52%
ROI -7.08%
52W High -34.04%
Beta 1.65
Dividend TTM -
Quick Ratio 4.40
Sales past 5Y 34.42%
Gross Margin 61.81%
52W Low 8.17%
ATR (14) 0.88
Dividend Ex-Date -
Current Ratio 4.66
EPS Y/Y TTM -99.73%
Oper. Margin -3.22%
RSI (14) 47.98
Volatility 4.55% 4.05%
Employees 815
Debt/Eq 0.01
Sales Y/Y TTM 21.76%
Profit Margin -20.61%
Recom 1.89
Target Price 30.83
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q -623.36%
Payout -
Rel Volume 1.30
Prev Close 19.57
Sales Surprise 6.77%
EPS Surprise -288.45%
Sales Q/Q 22.29%
Earnings May 07 AMC
Avg Volume 678.04K
Price 20.13
SMA20 0.96%
SMA50 -6.18%
SMA200 -16.75%
Trades
Volume 882,120
Change 2.86%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Reiterated
Needham
Buy
$30 → $33
Jan-18-23 Downgrade
Raymond James
Outperform → Mkt Perform
Jan-05-23 Initiated
Scotiabank
Sector Outperform
$33
Jan-07-22 Initiated
Stephens
Overweight
$52
Nov-18-21 Resumed
Goldman
Buy
$60
Jun-15-21 Initiated
Raymond James
Outperform
$45
Feb-18-21 Resumed
Needham
Buy
$88
Jan-28-21 Initiated
Truist
Buy
$61
Nov-10-20 Initiated
KeyBanc Capital Markets
Sector Weight
$48
Sep-09-20 Initiated
Morgan Stanley
Underweight
$35
Jul-31-19 Initiated
Lake Street
Buy
$35
Jul-02-19 Initiated
Needham
Buy
$33
Nov-29-18 Downgrade
Janney
Buy → Neutral
Oct-31-18 Upgrade
Janney
Neutral → Buy
Nov-07-17 Downgrade
Piper Jaffray
Overweight → Neutral
Nov-07-17 Downgrade
Janney
Buy → Neutral
Aug-31-17 Resumed
BTIG Research
Buy
$13
Nov-14-16 Resumed
Leerink Partners
Outperform
$12
Dec-18-15 Initiated
Cantor Fitzgerald
Buy
$13
Jun-11-15 Reiterated
Leerink Partners
Outperform
$11 → $13
Show Previous Ratings
Apr-22-24 05:00PM
08:30AM
Apr-16-24 08:30AM
Apr-02-24 10:33AM
Feb-27-24 05:55PM
03:20PM
Loading…
Feb-26-24 03:20PM
Feb-23-24 11:10AM
07:43AM
07:37AM
(Thomson Reuters StreetEvents)
Feb-22-24 06:05PM
05:03PM
(Associated Press Finance)
04:40PM
04:05PM
Feb-21-24 05:00PM
Feb-08-24 08:00AM
08:15AM
Loading…
Feb-06-24 08:15AM
Jan-08-24 08:00AM
Dec-12-23 04:30PM
Dec-01-23 04:05PM
Nov-29-23 08:30AM
Nov-22-23 08:30AM
Nov-08-23 04:39PM
Nov-07-23 04:57PM
(Associated Press Finance)
04:05PM
04:00PM
Nov-02-23 08:15AM
Oct-27-23 08:30AM
Oct-26-23 02:50PM
Oct-17-23 08:15AM
Oct-16-23 10:43AM
09:00AM
Loading…
Oct-12-23 09:00AM
Oct-04-23 04:05PM
Sep-28-23 04:05PM
08:15AM
Sep-27-23 09:00AM
Sep-21-23 04:05PM
Sep-07-23 04:05PM
Sep-06-23 08:15AM
Sep-02-23 06:15AM
Aug-29-23 08:15AM
Aug-22-23 08:15AM
Aug-15-23 04:15PM
Aug-08-23 06:05PM
04:55PM
04:05PM
Aug-01-23 08:15AM
Jul-19-23 05:00PM
Jul-08-23 08:43PM
Jun-20-23 08:31AM
Jun-12-23 08:31AM
May-30-23 06:56AM
May-25-23 05:13PM
May-24-23 09:00AM
May-23-23 05:00PM
May-22-23 07:30AM
May-12-23 06:15AM
May-05-23 01:59PM
May-04-23 06:25PM
04:05PM
09:45AM
May-03-23 05:44PM
08:30AM
May-02-23 04:05PM
May-01-23 05:35PM
Apr-29-23 04:31PM
Apr-27-23 04:05PM
10:02AM
09:55AM
Apr-18-23 09:48AM
Apr-17-23 08:30AM
Apr-13-23 05:00PM
Apr-12-23 08:30AM
Mar-23-23 06:54AM
Mar-15-23 04:15PM
11:44AM
Mar-11-23 12:11PM
Mar-10-23 09:30AM
Feb-27-23 05:00PM
Feb-24-23 05:42AM
Feb-22-23 06:15PM
04:05PM
Feb-15-23 08:36AM
Feb-13-23 05:23PM
10:14AM
Feb-06-23 05:00PM
Feb-01-23 04:05PM
08:32AM
Jan-24-23 10:23AM
Jan-23-23 09:00AM
Jan-18-23 06:10AM
Dec-22-22 08:54AM
Dec-21-22 09:08AM
Dec-15-22 04:05PM
Dec-12-22 12:00PM
Dec-01-22 02:46PM
(Investor's Business Daily)
Nov-09-22 06:15AM
Nov-02-22 06:55PM
04:05PM
Nov-01-22 05:11PM
Oct-27-22 05:00PM
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
EASTHAM KARIN Director Apr 01 '24 Option Exercise 13.19 10,000 131,900 43,125 Apr 02 04:17 PM EASTHAM KARIN Director Apr 01 '24 Sale 21.65 10,000 216,528 33,125 Apr 02 04:17 PM JONES EVAN/ FA Director Mar 01 '24 Option Exercise 13.19 10,000 131,900 47,601 Mar 05 05:28 PM JONES EVAN/ FA Director Mar 01 '24 Sale 24.36 10,000 243,599 37,601 Mar 05 05:28 PM JONES EVAN/ FA Director Jul 19 '23 Sale 30.17 3,090 93,232 35,173 Jul 24 05:06 PM JONES EVAN/ FA Director Jul 19 '23 Sale 30.14 838 25,257 37,601 Jul 24 05:06 PM BISHOP JOHN L Director Jul 18 '23 Option Exercise 6.37 10,000 63,700 43,125 Jul 19 08:35 PM BISHOP JOHN L Director Jul 18 '23 Sale 30.50 10,000 305,000 33,125 Jul 19 08:35 PM JONES EVAN/ FA Director Jul 18 '23 Sale 30.19 7,441 224,616 38,263 Jul 19 08:33 PM JONES EVAN/ FA Director Jul 18 '23 Sale 30.16 2,324 70,090 38,439 Jul 19 08:33 PM BISHOP JOHN L Director Jul 17 '23 Option Exercise 6.37 10,000 63,700 43,125 Jul 19 08:35 PM JONES EVAN/ FA Director Jul 17 '23 Sale 30.07 23,949 720,106 45,704 Jul 19 08:33 PM JONES EVAN/ FA Director Jul 17 '23 Sale 30.07 19,095 574,106 40,763 Jul 19 08:33 PM BISHOP JOHN L Director Jul 17 '23 Sale 30.00 10,000 300,002 33,125 Jul 19 08:35 PM Bhanji Muna Director Jun 16 '23 Sale 26.44 5,893 155,786 28,514 Jun 21 04:55 PM Bhanji Muna Director May 30 '23 Sale 25.91 1,539 39,875 24,733 Jun 01 05:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite